Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study

Abstract Purpose: MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Methods: Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (Parts 1A and 1B) or deep-seated lesions (Part 1D) were injected; patients had ≥1 noninjected lesions measurable per RECIST v1.1. Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (Part 1A) or concurrently (Parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results: As of February 27, 2023, 61 patients were treated. Patients had a median of 4 prior regimens (range, 1–17); 39 (63.9%) received prior anti-PD-(L)1 immunotherapy. Treatment-emergent adverse events (TEAEs) occurred in 96.7% of patients and 41.0% experienced Grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. Objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PRs). Duration of response was 2.7–22.3 months; median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti-PD-(L)1 therapy had PRs. Conclusions: MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-08-18
DOI
https://doi.org/10.1158/1078-0432.ccr-25-4865
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study

Nicholas M. Durham, Inderjit Mehmi, Anthony B. El-Khoueiry, Dmitriy Zamarin et al.
Clinical Cancer Research
RNA Interference and Gene Delivery
article

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study

Nicholas M. Durham, Inderjit Mehmi, Anthony B. El-Khoueiry, Dmitriy Zamarin, Omid Hamid, Vincent F. S. Dubois, Vivek Subbiah, Thomas U. Marron, Paula G. Fraenkel, A. Oberoi, Benedito A. Carneiro, Sandip Pravin Patel, Nairouz Elgeioushi, Emily C. Jennings, Xiaoru Chen, Analía Azaro, Eduardo Castañón Álvarez, Michael Abadier, Benjamin Ridgway, Zhongying Chen
article en

Abstract

Abstract Purpose: MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Methods: Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (Parts 1A and 1B) or deep-seated lesions (Part 1D) were injected; patients had ≥1 noninjected lesions measurable per RECIST v1.1. Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (Part 1A) or concurrently (Parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results: As of February 27, 2023, 61 patients were treated. Patients had a median of 4 prior regimens (range, 1–17); 39 (63.9%) received prior anti-PD-(L)1 immunotherapy. Treatment-emergent adverse events (TEAEs) occurred in 96.7% of patients and 41.0% experienced Grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. Objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PRs). Duration of response was 2.7–22.3 months; median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti-PD-(L)1 therapy had PRs. Conclusions: MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.

Clinical Cancer Research
University of Southern California (US), Hebron University (PS), Cedars-Sinai Medical Center (US), Palo Alto University (US), National Foundation for Cancer Research (US), Brown University (US), AstraZeneca (South Korea) (KR), Vall d'Hebron Institut de Recerca (ES), Angeles Clinic and Research Institute (US), Moderna Therapeutics (United States) (US), AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), AstraZeneca (Brazil) (BR), Tisch Hospital (US), AstraZeneca (Japan) (JP), Clinica Universidad de Navarra (ES), AstraZeneca (Poland) (PL), AstraZeneca (Spain) (ES), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 16%
RNA Interference and Gene Delivery
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.